Drug Approval | January 05, 2025
CDSCO approves Wockhardt’s Mignaf for treatment of community acquired bacterial pneumonia
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
Inaugurates new facilities to further NIMHANS’ mission of delivering cutting-edge care in mental health and neurosciences
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
Prithwish has close to 28 years of experience in a Commercial role
India's bio economy has experienced remarkable growth, skyrocketing from $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Subscribe To Our Newsletter & Stay Updated
